Aktiesnakken — August 2012
-
Jeg har læst at radioaktive stoffer vil vinde mere og mere frem fremover, men at det vil tage lang tid
-
men tror nu også selv at zevalin mest for sin berettigelse i de aller mest aggressive NHL patienter , hvor især Rituxan ikke virker.
-
Jeps 89
. Zevalin er et nicheprodukt (nichen kan dog blive stor) Arzerra har potentialet til at blive rigtig stort i mange indikationer. -
det ser ud som om US trækker alt op nu
-
sporvogn desværre
-
husk at tage noget profit golfy
-
I pandora?
-
er ikke godt nok inde i den. Men det er et godt spørgsmål....jeg har ikke nødvendigvis det rigtige svar.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind